Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro‐anabolic mediators
Aging Cell · 2025-01 · 24 (1)
DOI: 10.1111/acel.14361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 14.10.2024. Verfasst von Svenja Maurer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, Ulm, Germany. Hauptthemen laut MEDLINE: Quercetin, Chondrocytes, Dasatinib, Osteoarthritis. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Europäischer Sozialfonds, Ministry of Science, Research and Arts Baden-Württemberg, Collaborative Research Center CRC1149, funded by the German Research Foundation.
Abstract (Originalsprache)
Cellular senescence is associated with various age‐related disorders and is assumed to play a major role in the pathogenesis of osteoarthritis (OA). Based on this, we tested a senolytic combination therapy using Dasatinib (D) and Quercetin (Q) on aged isolated human articular chondrocytes (hACs), as well as in OA‐affected cartilage tissue (OARSI grade 1–2). Stimulation with D + Q selectively eliminated senescent cells in both, cartilage explants and isolated hAC. Furthermore, the therapy significantly promoted chondroanabolism, as demonstrated by increased gene expression levels of COL2A1, ACAN, and SOX9, as well as elevated collagen type II and glycosaminoglycan biosynthesis. Additionally, D + Q treatment significantly reduced the release of SASP factors (IL6, CXCL1). RNA sequencing analysis revealed an upregulation of the anabolic factors, inter alia, FGF18, IGF1, and TGFB2, as well as inhibitory effects on cytokines and the YAP‐1 signaling pathway, explaining the underlying mechanism of the chondroanabolic promotion upon senolytic treatment. Accordingly, stimulation of untreated hAC with conditioned medium of D + Q‐treated cells similarly induced the expression of chondrogenic markers. Detailed analyses demonstrated that chondroanabolic effects could be mainly attributed to Dasatinib, while monotherapeutical application of Quercetin or Navitoclax did not promote the chondroanabolism. Overall, D + Q therapy restored the chondrogenic phenotype in OA hAC most likely by creating a pro‐chondroanabolic environment through the reduction of SASP factors and upregulation of growth factors. This senolytic approach could therefore be a promising candidate for further testing as a disease‐modifying osteoarthritis drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, Ulm, Germany.
ORCID-Profile: Jana Riegger
Förderung
- Europäischer Sozialfonds
- Ministry of Science, Research and Arts Baden-Württemberg
- Collaborative Research Center CRC1149, funded by the German Research Foundation
Zitieren
APA
Maurer, S., Kirsch, V., Ruths, L., Brenner, R. E., & Riegger, J. (2025). Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro‐anabolic mediators. Aging Cell, 24(1). https://doi.org/10.1111/acel.14361
Vancouver
Maurer S, Kirsch V, Ruths L, Brenner RE, Riegger J. Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro‐anabolic mediators. Aging Cell. 2025;24(1). doi:10.1111/acel.14361
BibTeX
@article{Maurer2025,
author = {Maurer, Svenja and Kirsch, Valeria and Ruths, Leonie and Brenner, Rolf E and Riegger, Jana},
title = {Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro‐anabolic mediators},
journal = {Aging Cell},
year = {2025},
volume = {24},
number = {1},
doi = {10.1111/acel.14361}
}
EUVIMED